Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
COVID-19
SARS-CoV-2
intranasal
vaccine
virus-like particles
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
22
03
2022
received:
29
09
2021
accepted:
23
03
2022
pubmed:
12
4
2022
medline:
10
8
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
The highly contagious SARS-CoV-2 is mainly transmitted by respiratory droplets and aerosols. Consequently, people are required to wear masks and maintain a social distance to avoid spreading of the virus. Despite the success of the commercially available vaccines, the virus is still uncontained globally. Given the tropism of SARS-CoV-2, a mucosal immune reaction would help to reduce viral shedding and transmission locally. Only seven out of hundreds of ongoing clinical trials are testing the intranasal delivery of a vaccine against COVID-19. In the current study, we evaluated the immunogenicity of a traditional vaccine platform based on virus-like particles (VLPs) displaying RBD of SARS-CoV-2 for intranasal administration in a murine model. The candidate vaccine platform, CuMV CuMV Our data demonstrate that intranasal administration of CuMV
Sections du résumé
BACKGROUND
The highly contagious SARS-CoV-2 is mainly transmitted by respiratory droplets and aerosols. Consequently, people are required to wear masks and maintain a social distance to avoid spreading of the virus. Despite the success of the commercially available vaccines, the virus is still uncontained globally. Given the tropism of SARS-CoV-2, a mucosal immune reaction would help to reduce viral shedding and transmission locally. Only seven out of hundreds of ongoing clinical trials are testing the intranasal delivery of a vaccine against COVID-19.
METHODS
In the current study, we evaluated the immunogenicity of a traditional vaccine platform based on virus-like particles (VLPs) displaying RBD of SARS-CoV-2 for intranasal administration in a murine model. The candidate vaccine platform, CuMV
RESULTS
CuMV
CONCLUSION
Our data demonstrate that intranasal administration of CuMV
Identifiants
pubmed: 35403221
doi: 10.1111/all.15311
pmc: PMC9111403
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Virus-Like Particle
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2446-2458Informations de copyright
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Bio Protoc. 2017 May 20;7(10):
pubmed: 29082285
Vaccine. 2005 Apr 8;23(20):2565-72
pubmed: 15780438
Int J Infect Dis. 2021 May;106:61-64
pubmed: 33713819
Nat Immunol. 2019 Jan;20(1):97-108
pubmed: 30510223
Sci Rep. 2021 Jul 30;11(1):15531
pubmed: 34330945
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Front Immunol. 2020 Nov 30;11:611337
pubmed: 33329607
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Heliyon. 2021 Jan;7(1):e05850
pubmed: 33392409
Allergy. 2022 Aug;77(8):2446-2458
pubmed: 35403221
J Immunol. 2004 Aug 1;173(3):1978-86
pubmed: 15265932
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
J Virol Methods. 2021 Nov;297:114261
pubmed: 34403775
J Immunol. 2009 Sep 15;183(6):3788-99
pubmed: 19710454
NPJ Vaccines. 2021 Jan 4;6(1):2
pubmed: 33398006
Mol Cell. 2020 Sep 3;79(5):710-727
pubmed: 32853546
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Arch Immunol Ther Exp (Warsz). 2009 Sep-Oct;57(5):311-23
pubmed: 19688186
Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578
pubmed: 28933664
Nat Commun. 2020 Jan 8;11(1):120
pubmed: 31913287
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315826
Eur J Immunol. 2008 Jan;38(1):114-26
pubmed: 18081037
Curr Top Microbiol Immunol. 2012;354:1-18
pubmed: 21053117
Allergy. 2022 Jan;77(1):243-257
pubmed: 34496033
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
NPJ Vaccines. 2021 Aug 24;6(1):107
pubmed: 34429427
J Virol. 2005 Dec;79(23):14614-21
pubmed: 16282461
Front Immunol. 2019 Apr 05;10:736
pubmed: 31024563
Semin Immunol. 2017 Dec;34:123-132
pubmed: 28887001
NPJ Vaccines. 2017 Oct 23;2:30
pubmed: 29263885
J Immunol. 1998 Sep 15;161(6):3026-32
pubmed: 9743367
PLoS One. 2013 Oct 18;8(10):e76571
pubmed: 24204639
Vet Microbiol. 2002 Feb 26;85(1):69-82
pubmed: 11792494
Sci Immunol. 2017 Jun 2;2(12):
pubmed: 28783656
Allergy. 2022 Jan;77(1):143-149
pubmed: 34240429
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Vaccines (Basel). 2021 Apr 16;9(4):
pubmed: 33923573
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547
Immunol Rev. 2020 Jul;296(1):155-168
pubmed: 32472710
Allergy. 2021 Sep;76(9):2895-2998
pubmed: 33948956